Compare Koken Ltd. with Similar Stocks
Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
2
With a growth in Net Profit of 637.5%, the company declared Very Positive results in Dec 25
3
With ROCE of 7.54%, it has a very attractive valuation with a 0.71 Enterprise value to Capital Employed
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 9,693 Million (Micro Cap)
10.00
NA
0.05%
0.21
5.88%
0.73
Revenue and Profits:
Net Sales:
4,413 Million
(Quarterly Results - Dec 2025)
Net Profit:
521 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.2%
0%
6.2%
6 Months
7.9%
0%
7.9%
1 Year
17.71%
0%
17.71%
2 Years
19.36%
0%
19.36%
3 Years
20.39%
0%
20.39%
4 Years
5.91%
0%
5.91%
5 Years
-3.55%
0%
-3.55%
Koken Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.20%
EBIT Growth (5y)
7.99%
EBIT to Interest (avg)
24.25
Debt to EBITDA (avg)
1.82
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
0.58
Tax Ratio
26.32%
Dividend Payout Ratio
23.96%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.16%
ROE (avg)
6.43%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
0.66
EV to EBIT
9.35
EV to EBITDA
6.78
EV to Capital Employed
0.71
EV to Sales
0.97
PEG Ratio
0.18
Dividend Yield
0.06%
ROCE (Latest)
7.54%
ROE (Latest)
6.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
4,413.10
2,353.10
87.54%
Operating Profit (PBDIT) excl Other Income
839.40
210.70
298.39%
Interest
16.10
15.70
2.55%
Exceptional Items
0.00
0.00
Consolidate Net Profit
520.80
70.60
637.68%
Operating Profit Margin (Excl OI)
164.10%
44.80%
11.93%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 87.54% vs 4.09% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 637.68% vs 111.38% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
11,857.10
10,762.40
10.17%
Operating Profit (PBDIT) excl Other Income
1,688.10
1,451.00
16.34%
Interest
59.70
47.50
25.68%
Exceptional Items
0.00
31.60
-100.00%
Consolidate Net Profit
885.30
722.10
22.60%
Operating Profit Margin (Excl OI)
107.20%
93.80%
1.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 10.17% vs 1.66% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 22.60% vs 3.00% in Dec 2024
About Koken Ltd. 
Koken Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






